New hope for Tough-to-Treat colon cancer: experimental combo enters testing
NCT ID NCT07147231
Summary
This study is testing the safety and effectiveness of a new two-drug combination for people with advanced colorectal cancer that has stopped responding to standard treatments. The trial combines an experimental drug (pidnarulex) that aims to stop cancer cell growth with an immunotherapy drug (cemiplimab) that helps the immune system fight the cancer. It will enroll about 86 adults to find the best dose and see if the combination can help control the cancer for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.